{"id":1060,"date":"2012-06-15T19:15:25","date_gmt":"2012-06-15T19:15:25","guid":{"rendered":"https:\/\/blogs.bmj.com\/jfprhc\/?p=1060"},"modified":"2012-06-15T19:15:25","modified_gmt":"2012-06-15T19:15:25","slug":"safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/","title":{"rendered":"Safer prescribing of therapeutic norethisterone for women at risk of VTE"},"content":{"rendered":"<h2>Latest Online First article<\/h2>\n<p><a href=\"http:\/\/jfprhc.bmj.com\/content\/early\/2012\/06\/11\/jfprhc-2012-100345.short?g=w_jfprhc_ahead_tab\" target=\"_blank\"><strong>Norethisterone and VTE risk<\/strong><\/a><\/p>\n<p>Diana Mansour highlights a change in the Summary of Product Characteristics for Primolut N\u00ae, since data have emerged showing that, in high doses, norethisterone is partly metabolised to estradiol. This only applies to this particular progestogen, and only in high doses, not those used in contraceptive pills. Nevertheless, it could explain why studies have occasionally suggested an increased risk of venous thromboembolism with high-dose norethisterone, used therapeutically for the management of menorrhagia or dysfunctional uterine bleeding. <em>from Anne Szarewski, Editor in Chief<\/em>, <em>JFPRHC<\/em><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Latest Online First article Norethisterone and VTE risk Diana Mansour highlights a change in the Summary of Product Characteristics for Primolut N\u00ae, since data have emerged showing that, in high doses, norethisterone is partly metabolised to estradiol. This only applies to this particular progestogen, and only in high doses, not those used in contraceptive pills. [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7420,1141],"tags":[2486],"class_list":["post-1060","post","type-post","status-publish","format-standard","hentry","category-clinical-practice","category-news","tag-clinical-practice"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Safer prescribing of therapeutic norethisterone for women at risk of VTE - BMJ Sexual &amp; Reproductive Health blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Safer prescribing of therapeutic norethisterone for women at risk of VTE - BMJ Sexual &amp; Reproductive Health blog\" \/>\n<meta property=\"og:description\" content=\"Latest Online First article Norethisterone and VTE risk Diana Mansour highlights a change in the Summary of Product Characteristics for Primolut N\u00ae, since data have emerged showing that, in high doses, norethisterone is partly metabolised to estradiol. This only applies to this particular progestogen, and only in high doses, not those used in contraceptive pills. [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/\" \/>\n<meta property=\"og:site_name\" content=\"BMJ Sexual &amp; Reproductive Health blog\" \/>\n<meta property=\"article:published_time\" content=\"2012-06-15T19:15:25+00:00\" \/>\n<meta name=\"author\" content=\"BMJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BMJ\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/2012\\\/06\\\/15\\\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/2012\\\/06\\\/15\\\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\\\/\"},\"author\":{\"name\":\"BMJ\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\"},\"headline\":\"Safer prescribing of therapeutic norethisterone for women at risk of VTE\",\"datePublished\":\"2012-06-15T19:15:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/2012\\\/06\\\/15\\\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\\\/\"},\"wordCount\":102,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/#organization\"},\"keywords\":[\"Clinical practice\"],\"articleSection\":[\"Clinical practice\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/2012\\\/06\\\/15\\\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/2012\\\/06\\\/15\\\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/2012\\\/06\\\/15\\\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\\\/\",\"name\":\"Safer prescribing of therapeutic norethisterone for women at risk of VTE - BMJ Sexual &amp; Reproductive Health blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/#website\"},\"datePublished\":\"2012-06-15T19:15:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/2012\\\/06\\\/15\\\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/2012\\\/06\\\/15\\\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/2012\\\/06\\\/15\\\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Safer prescribing of therapeutic norethisterone for women at risk of VTE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/\",\"name\":\"BMJ Sexual &amp; Reproductive Health blog\",\"description\":\"For readers of the journal and health professionals in contraception and sexual health care.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/#organization\",\"name\":\"BMJ Sexual &amp; Reproductive Health blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/files\\\/2017\\\/11\\\/blog-logo-bmj-srh.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/files\\\/2017\\\/11\\\/blog-logo-bmj-srh.png\",\"width\":328,\"height\":34,\"caption\":\"BMJ Sexual &amp; Reproductive Health blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\",\"name\":\"BMJ\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"caption\":\"BMJ\"},\"sameAs\":[\"https:\\\/\\\/blogs.bmj.com\\\/\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjsrh\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Safer prescribing of therapeutic norethisterone for women at risk of VTE - BMJ Sexual &amp; Reproductive Health blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/","og_locale":"en_US","og_type":"article","og_title":"Safer prescribing of therapeutic norethisterone for women at risk of VTE - BMJ Sexual &amp; Reproductive Health blog","og_description":"Latest Online First article Norethisterone and VTE risk Diana Mansour highlights a change in the Summary of Product Characteristics for Primolut N\u00ae, since data have emerged showing that, in high doses, norethisterone is partly metabolised to estradiol. This only applies to this particular progestogen, and only in high doses, not those used in contraceptive pills. [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/","og_site_name":"BMJ Sexual &amp; Reproductive Health blog","article_published_time":"2012-06-15T19:15:25+00:00","author":"BMJ","twitter_card":"summary_large_image","twitter_misc":{"Written by":"BMJ"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/"},"author":{"name":"BMJ","@id":"https:\/\/blogs.bmj.com\/bmjsrh\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe"},"headline":"Safer prescribing of therapeutic norethisterone for women at risk of VTE","datePublished":"2012-06-15T19:15:25+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/"},"wordCount":102,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/bmjsrh\/#organization"},"keywords":["Clinical practice"],"articleSection":["Clinical practice","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/","url":"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/","name":"Safer prescribing of therapeutic norethisterone for women at risk of VTE - BMJ Sexual &amp; Reproductive Health blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmjsrh\/#website"},"datePublished":"2012-06-15T19:15:25+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/bmjsrh\/2012\/06\/15\/safer-prescribing-of-therapeutic-norethisterone-for-women-at-risk-of-vte\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/bmjsrh\/"},{"@type":"ListItem","position":2,"name":"Safer prescribing of therapeutic norethisterone for women at risk of VTE"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/bmjsrh\/#website","url":"https:\/\/blogs.bmj.com\/bmjsrh\/","name":"BMJ Sexual &amp; Reproductive Health blog","description":"For readers of the journal and health professionals in contraception and sexual health care.","publisher":{"@id":"https:\/\/blogs.bmj.com\/bmjsrh\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/bmjsrh\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/bmjsrh\/#organization","name":"BMJ Sexual &amp; Reproductive Health blog","url":"https:\/\/blogs.bmj.com\/bmjsrh\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmjsrh\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/bmjsrh\/files\/2017\/11\/blog-logo-bmj-srh.png","contentUrl":"https:\/\/blogs.bmj.com\/bmjsrh\/files\/2017\/11\/blog-logo-bmj-srh.png","width":328,"height":34,"caption":"BMJ Sexual &amp; Reproductive Health blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmjsrh\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/bmjsrh\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe","name":"BMJ","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","caption":"BMJ"},"sameAs":["https:\/\/blogs.bmj.com\/"],"url":"https:\/\/blogs.bmj.com\/bmjsrh\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/bmjsrh\/wp-json\/wp\/v2\/posts\/1060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/bmjsrh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/bmjsrh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmjsrh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmjsrh\/wp-json\/wp\/v2\/comments?post=1060"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/bmjsrh\/wp-json\/wp\/v2\/posts\/1060\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/bmjsrh\/wp-json\/wp\/v2\/media?parent=1060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmjsrh\/wp-json\/wp\/v2\/categories?post=1060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmjsrh\/wp-json\/wp\/v2\/tags?post=1060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}